$1.48 +0.02 (1.32%)

Allarity Therapeutics, Inc. Common Stock (ALLR)

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment. The company specializes in identifying targeted therapies based on tumor biology and genetic profiles to improve patient outcomes. Previously known as Oncothyreon Inc., Allarity aims to advance its pipeline through research and partnerships in oncology.

🚫 Allarity Therapeutics, Inc. Common Stock does not pay dividends

Company News

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
GlobeNewswire Inc. • Allarity Therapeutics • September 22, 2025

Allarity Therapeutics presented promising Phase 2 clinical trial data for stenoparib, a dual PARP and WNT pathway inhibitor for advanced ovarian cancer. The study showed median overall survival exceeding 25 months, with potential benefits for patients with different genetic backgrounds.

Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Benzinga • Avi Kapoor • July 24, 2024

Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.

All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
Zacks Investment Research • Zacks Equity Research • May 7, 2024

Allarity Therapeutics, Inc. (ALLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

High-Potential: A Short Guide to Penny Stock Investing
PennyStocks • J Dylan • March 21, 2023

Use these tips for finding high potential penny stocks The post High-Potential: A Short Guide to Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.